Welcome to our dedicated page for Acutus Medical SEC filings (Ticker: AFIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Acutus Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Acutus Medical's regulatory disclosures and financial reporting.
Acutus Medical, Inc. amendment to a Schedule 13G/A reports updated beneficial ownership disclosures by Advent Life Sciences LLP, Advent Life Sciences Fund I LP and Dr. Shahzad Malik.
The filing states Advent Life Sciences LLP and Advent Life Sciences Fund I LP each hold 0 shares. Dr. Shahzad Malik holds 3,281 restricted shares of common stock and options to purchase 19,476 shares, representing 0.07608% of the class. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest. Signatures are dated 02/13/2026.